Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMOPLQI)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
VU 0238429; 1160247-92-6; VU0238429; 1-(4-METHOXYBENZYL)-5-TRIFLUOROMETHOXYISATIN; CHEMBL466253; VU-0238429; 1-[(4-Methoxyphenyl)methyl]-5-(trifluoromethoxy)-1H-indole-2,3-dione; GTPL3257; CTK8E8884; DTXSID40655290; MolPort-023-276-878; cid_42633508; ML129; MFCD16618396; BDBM50258656; ZINC40875741; AKOS024457724; API0008325; HY-12157; KB-81463; RT-017613; B7448; CS-0003122; VU0238429-1; VU0238429, solubility: >=20 mg/mL in DMSO; J-003368; 1-(4-methoxybenzyl)-5-(trifluoromethoxy)indoline-2,3-dione
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||
